Abstract Number: 0835 • ACR Convergence 2023
Abatacept in Individuals at Risk of Developing Rheumatoid Arthritis: Results from the Arthritis Prevention in the Pre-clinical Phase of RA with Abatacept (APIPPRA) Trial
Background/Purpose: The definition of higher risk states for rheumatoid arthritis (RA) has been refined in more recent years through inclusion of serum autoantibodies and symptom…Abstract Number: 0982 • ACR Convergence 2023
Systemic Autoimmune Rheumatic Diseases (SARD) in the Agricultural Health Study Cohort: Rates of Rheumatoid Arthritis (RA) and Other SARD Among Medicare-linked Participants
Background/Purpose: Some systemic autoimmune rheumatic diseases (SARD), such as rheumatoid arthritis (RA) and systemic lupus erythematosus (SLE), have been associated with farming, specific pesticides, and…Abstract Number: 1034 • ACR Convergence 2023
The Relationship Between the Extent of Ground Glass to Fibrosis Ratio and Treatment Response to Immunomodulatory Therapy in Three Separate Autoimmune Interstitial Lung Disease Cohorts
Background/Purpose: For patients with autoimmune interstitial lung disease (ILD), the clinician's interpretation of the extent of ground glass relative to fibrosis on imaging often influences…Abstract Number: 1265 • ACR Convergence 2023
Changes in the Endocannabinoid Tone in Rheumatoid Arthritis and Osteoarthritis – Discovery of a Novel Target for the Treatment of Pain and Inflammation?
Background/Purpose: Inflammation is a complicated physiological process that results in a variety of disorders. Several inflammatory mediators are produced during this process, which is responsible…Abstract Number: 1281 • ACR Convergence 2023
Risk of Cancer in Patients with Rheumatoid Arthritis Under Tocilizumab: Data from the French National Registry REGATE
Background/Purpose: Our study aimed to estimate the incidence and risk factors of cancer among rheumatoid arthritis (RA) patients treated with tocilizumab (TCZ) and followed for…Abstract Number: 1297 • ACR Convergence 2023
COVID-19 Vaccination-related Delayed Adverse Events Among Patients with Rheumatoid Arthritis: Results from the COVAD Study
Background/Purpose: COVID-19 vaccines have been proven to be safe in the healthy population. Data on longer-term AEs in people with autoimmune diseases (AIDs), including rheumatoid…Abstract Number: 1313 • ACR Convergence 2023
Remotely Supervised Weight Loss and Exercise Training Improves Disease Activity and Patient Reported Outcomes in Older Patients with Rheumatoid Arthritis
Background/Purpose: Older persons with rheumatoid arthritis (RA) are at increased risk for sarcopenic obesity, physical disability, adverse drug events, and cardiovascular disease; thus, there is…Abstract Number: 1330 • ACR Convergence 2023
Certolizumab-pegol, Abatacept, Tocilizumab or Active Conventional Therapy in Early Rheumatoid Arthritis: 48 Week Patient-reported Outcomes of the NORD-STAR Trial
Background/Purpose: The optimal first-line treatment of patients with early rheumatoid arthritis (eRA) is not established. Methods: In this investigator-initiated, randomized, open-label study (NCT01491815), patients with…Abstract Number: 1347 • ACR Convergence 2023
Continuing Biologic DMARDs During Pregnancy in Women with Rheumatic Disease Was Not Associated with Increased Unfavorable Pregnancy Outcomes, Serious Infections, and Adverse Effects of Vaccination
Background/Purpose: It is important to control disease activity during pregnancy in women with rheumatic diseases because its exacerbation is associated with increased adverse pregnancy outcomes.…Abstract Number: 1676 • ACR Convergence 2023
Tofacitinib Accelerates in Vitro Clot Formation and Delays Clot Lysis in Rheumatoid Arthritis Blood by Enhancement of Macrophage TLR4 Mediated Cytokine Responses- a New Angle on Thrombosis with JAKi in Rheumatology
Background/Purpose: Rheumatoid Arthritis (RA) patients treated with Janus Kinase inhibitors (JAKi) have reportedly higher venous thromboembolism (VTE) risk and atherosclerotic-related complications including myocardial infarction (1).Although…Abstract Number: 1731 • ACR Convergence 2023
A Competitive Inhibitor of MOART Showed Potent Therapeutic Effects in a Mouse Model of Collagen-induced Arthritis
Background/Purpose: Despite tumor necrosis factor (TNF) inhibitors and Jak kinase inhibitors (JKI) have shown a significant advance in the treatment of rheumatoid arthritis (RA) however,…Abstract Number: 1747 • ACR Convergence 2023
A Newly Described Cytokine interleukin-40 Is Increased in the Serum of Individuals At-risk of Rheumatoid Arthritis and Induces an Inflammatory Response in Mononuclear Cells
Background/Purpose: Interleukin-40 (IL-40) is a newly described cytokine related to malignancies and immunity function. We have previously shown that IL-40 is up-regulated in early stages…Abstract Number: 1763 • ACR Convergence 2023
Asthma Severity Is Associated Increased Serum Anti-cyclic Antibody Level at Baseline and in Increase During Longitudinal Follow-up
Background/Purpose: The lung airways have been implicated in the pathogenesis of RA. RA-associated autoantibodies, including anti-cyclic citrullinated peptide (anti-CCP) antibodies are found to be generated…Abstract Number: 1847 • ACR Convergence 2023
Influence of Seasonal Changes on Adherence in Rheumatoid Arthritis Patients
Background/Purpose: Rheumatoid arthritis (RA) symptoms are suspected to be linked with exposure to colder environments. Previous studies on RA and seasonality have focused on RA…Abstract Number: 1911 • ACR Convergence 2023
Using the Technology Acceptance Model to Assess Physician Perceptions and Experiences Using the Rheumatoid Arthritis-Patient-Reported Outcomes Dashboard: Mixed-Methods Study
Background/Purpose: Improving shared decision-making using a treat-to-target approach, including the use of patient reported outcomes (PROs), is important to providing high quality care for rheumatoid…
- « Previous Page
- 1
- …
- 53
- 54
- 55
- 56
- 57
- …
- 188
- Next Page »